← Back to Search

Rewards Sensitivity After Brain Injury

N/A
Waitlist Available
Led By Shira Cohen-Zimerman, PhD
Research Sponsored by Shirley Ryan AbilityLab
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes
Awards & highlights
No Placebo-Only Group

Summary

A study measuring rewards sensitivity in individuals with acquired brain injury at an acute rehabilitation level.

Eligible Conditions
  • Brain Injury

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Electrodermal activity (EDA) before, during and after the Cued Response Reaction task
Performance on a Cued Response Reaction Time Task, in each of the three rewards conditions (Dollar, Penny, No reward)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Non-impaired controlsExperimental Treatment1 Intervention
Measuring the effect of three different types of rewards (one dollar, one penny, and no reward) on performance in a cognitive test.
Group II: Individuals with Acquired Brain InjuryExperimental Treatment1 Intervention
Measuring the effect of three different types of rewards (one dollar, one penny, and no reward) on performance in a cognitive test.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Type of reward presented
2021
N/A
~40

Find a Location

Who is running the clinical trial?

Shirley Ryan AbilityLabLead Sponsor
208 Previous Clinical Trials
17,894 Total Patients Enrolled
Shira Cohen-Zimerman, PhDPrincipal InvestigatorShirley Ryan AbilityLab
2 Previous Clinical Trials
120 Total Patients Enrolled
~7 spots leftby Jan 2026